Anti-EGFR monoclonal antibodies which act as EGF, TGFα, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours

International Journal of Cancer

Volumn 75, Issue 2, 1998, Pages 310-316

  Modjtahedi, Helmout ^a   Komurasaki, Toshi ^b   Toyoda, Hitoshi ^b   Dean, Christopher ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY;

ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; EPIDERMAL GROWTH FACTOR; GROWTH SUBSTANCES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 0032545687     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980119)75:2<310::AID-IJC22>3.0.CO;2-F     Document Type: Article

References (24)

1. BEERLI, R.R. and HYNES, N.E., Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differ in their biological activities. J. biol. Chem., 271, 6071-6076 (1996).
2. COWLEY, G., SMITH, J.A. and GUSTERSON, B., The amount of EGF receptor is elevated on squamous cell carcinomas. Cancer Cells, 1, 5-10 (1984).
3. DEAN, C.J., MODJTAHEDI, H., ECCLES, S., BOX, G. and STYLES, J., Immunotherapy, with antibodies to the EGF receptor. Int. J. Cancer, Suppl. 8, 103-107 (1994).
4. DERYNCK, R., Transforming growth factor α. Adv. Cancer Res., 58, 27-52 (1992).
5. EARP, H.S., DAWSON, T.L., LI, X. and YU, H., Heterodimorization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35, 115-132 (1995).
6. ELENIUS, K., PAUL, S., ALLISON, G., SUN, J. and KLAGSBRUN, M., Activation of HER4 by heparin-binding EGF like growth factor stimulates chemotaxis but not proliferation. EMBO J., 16, 1268-1278 (1997).
7. FILMUS, J., POLLAK, M.N., CAILLEAU, R. and BUICK, R.N., MDA-468, a human breast carcinoma cell line with a high number of epidermal growth factor receptor, has an amplified EGF receptor and is growth inhibited by EGF. Biochem. biophys. Res. Comm., 128, 898-905 (1985).
8. KOMURASAKI, T., TOYODA, H., UCHIDA, D. and MORIMOTO, S., Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor. ErbB-2, ErbB-3 and ErbB-4. Oncogene 15, 2841-2848 (1997).
9. LEWIS, G.D., LOFGREN, J.A., MCMURTREY, A.E., NUIJEN, A., FENDLY, B.M., BAUER, K.D. and SLIWKOWSKI, M.X., Growth regulation of human breast and ovarian tumour cells by heregulin: evidence for the requirment of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56, 1457-1465 (1996).
10. MASON, and GULLICK, W.J., Type 1 growth factor receptors: an overview of recent development. Breast, 4, 11-18 (1995).
11. MENDELSOHN, J., EGF receptor blockade as anticancer therapy. Proc. Amer. Ass. Cancer Res., 37, 647-748 (1996).
12. MODJTAHEDI, H., COHEN, B. and DEAN, C., Monoclonal antibodies directed against the EGF receptor show differential bindings of amphiregulin and EGF to the EGF receptor. Int. J. Oncol., 10, 339-347 (1997).
13. MODJTAHEDI, H. and DEAN, C., The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (Review). Int. J. Oncol., 4, 277-296 (1994).
14. MODJTAHEDI, H. and DEAN, C., The binding of HB-EGF to tumour cells is blocked by MAbs which act as EGF and TGFα antagonists. Biochem. biophys. Res. Comm., 207, 389-397 (1995).
15. MODJTAHEDI, H. and DEAN, C., Monoclonal antibodies to the EGF receptor act as betacellulin antagonists. Biochem. biophys. Res. Comm., 221, 625-630 (1996).
16. MODJTAHEDI, H. and 13 OTHERS, A phase I trial and tumour localization of the anti-EGFR antibody ICR62 in head and neck or lung cancer. Brit. J. Cancer. 73, 228-235 (1996).
17. MODJTAHEDI, H., STYLES, J., BOX, G., ECCLES, S., GUSTERSON, B. and DEAN, C., Antitumour activity of rat mAbs to the human receptor for EGF. In: A.A. Epenetos and N.R. Lemoine (eds.), Mutant oncogenes: targets for therapy? pp. 35-47, Chapman and Hall, London (1993a).
18. MODJTAHEDI, H., STYLES, J.M. and DEAN, C.J., The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468, Brit. J. Cancer, 67, 247-253 (1993b).
19. MODJTAHEDI, H., STYLES, J. and DEAN, C., The growth response of human tumour cell lines overexpressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding. Int. J. Oncol., 3, 237-243 (1993c).
20. RIESE, D., KIM, E.D., ELENIUS, K., BUCKLEY, S., KLAGSBRUN, M., PLOWMAN, G.D. and STERN, D.F., The epidermal growth factor receptor couples TGFα. HB-EGF and amphiregulin to NEU, ErbB-3 and ErbB-4. J. biol. Chem., 271, 20047-20052 (1996).
21. SALOMON, D.S., BRADT, R., CIARDIELLO, F. and NORMANNO, N., Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol., 19, 183-232 (1995).
22. TOYODA, H., KOMURASAKI, T., IKEDA, Y., YOSHIMOTO, M. and MORIMOTO, S., Molecular cloning of mouse epiregulin, a novel epidermal growth factor related protein, expressed in the early stage of development. FEBS Lett., 377, 403-407 (1995a).
23. TOYODA, H., KOMURASAKI, T., UCHIDA, D., TAKAYAMA, Y., ISOBE, T., OKUYAMA, T. and HANADA, K., Epiregulin: a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J. biol. Chem., 13, 7495-7500 (19950).
24. YAMAGATA, H., NAKAHATA, K., SUSUKI, Y., KAKINUMA, A., TSUKAGOSHI, N. and UDAKA, S., Use of Bacillus brevis for efficient synthesis and secretion of human epidermal growth factor. Proc. nat. Acad. Sci. (Wash.), 86, 3580-3593 (1989).